Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00472797
Status:
COMPLETED
Last Update Posted:
2013-08-07
First Post:
2007-05-10
Brief Title:
Rebif New Formulation RNF Quality of Life QOL Study
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
A Randomized Multicenter Two-arm 12 Week Phase IIIb Study to Evaluate Quality of Life QOL Measures in Subjects With Relapsing Forms of Multiple Sclerosis MS Who Are Transitioning From Rebif Interferon Beta-1a to Rebif New Formulation RNF
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RebiQoL
Brief Summary:
To evaluate the impact on Quality of Life QOL tolerability treatment satisfaction and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif RNF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None